DK200000375U1 - Polypeptidsammensætninger med forbedret stabilitet. - Google Patents

Polypeptidsammensætninger med forbedret stabilitet.

Info

Publication number
DK200000375U1
DK200000375U1 DK200000375U DKBA200000375U DK200000375U1 DK 200000375 U1 DK200000375 U1 DK 200000375U1 DK 200000375 U DK200000375 U DK 200000375U DK BA200000375 U DKBA200000375 U DK BA200000375U DK 200000375 U1 DK200000375 U1 DK 200000375U1
Authority
DK
Denmark
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
DK200000375U
Other languages
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Vincent Rinella Junior Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000375(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK200000375U1 publication Critical patent/DK200000375U1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK200000375U 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet. DK200000375U1 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08

Publications (1)

Publication Number Publication Date
DK200000375U1 true DK200000375U1 (da) 2001-03-16

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200000375U DK200000375U1 (da) 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet.

Country Status (15)

Country Link
EP (1) EP1242121B1 (da)
JP (1) JP2003523972A (da)
CN (1) CN1409640A (da)
AT (1) ATE288765T1 (da)
AU (1) AU777570B2 (da)
BR (1) BR0016334A (da)
CA (1) CA2394213A1 (da)
DE (2) DE60018105T2 (da)
DK (1) DK200000375U1 (da)
EA (1) EA004631B1 (da)
ES (1) ES2236010T3 (da)
IL (1) IL150129A0 (da)
PL (1) PL355378A1 (da)
PT (1) PT1242121E (da)
WO (1) WO2001043762A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CA2502825A1 (en) * 2002-10-22 2004-05-06 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
CA2545034C (en) 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
EP1687248B1 (en) 2003-11-20 2011-06-01 SOLVAY (Société Anonyme) Process for producing dichloropropanol from glycerol and a chlorinated agent and in the presence of a catalyst selected from adipic and glutaric acid
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
EP1817048B1 (en) 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
DE502007003700D1 (de) * 2006-07-27 2010-06-24 Cognis Ip Man Gmbh Verfahren zur Herstellung von Glycerin
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
LT2611458T (lt) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
DK2433651T3 (da) 2010-09-03 2013-04-08 Aug Hedinger Gmbh & Co Kg Fremgangsmåde til bestemmelse af aldehyder og ketoner i glycerin
EP2621911A1 (en) 2010-09-30 2013-08-07 Solvay Sa Derivative of epichlorohydrin of natural origin
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
BR112019011761A2 (pt) 2016-12-16 2019-11-05 Novo Nordisk As composições farmacêuticas contendo insulina
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
US20230018324A1 (en) * 2019-12-06 2023-01-19 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
EP4106724A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
CA3193994A1 (en) * 2020-10-08 2022-04-14 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
WO2024081659A1 (en) * 2022-10-13 2024-04-18 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189964B1 (pl) * 1996-06-20 2005-10-31 Novo Nordisk As Wodny preparat insuliny, środek farmaceutyczny dopodawania pozajelitowego oraz sposób poprawiania chemicznej stabilności preparatów insuliny

Also Published As

Publication number Publication date
WO2001043762A2 (en) 2001-06-21
AU777570B2 (en) 2004-10-21
EP1242121B1 (en) 2005-02-09
CA2394213A1 (en) 2001-06-21
JP2003523972A (ja) 2003-08-12
PT1242121E (pt) 2005-05-31
EA004631B1 (ru) 2004-06-24
PL355378A1 (en) 2004-04-19
DE60018105D1 (de) 2005-03-17
DE60018105T2 (de) 2005-12-29
AU2049301A (en) 2001-06-25
EP1242121A2 (en) 2002-09-25
EA200200684A1 (ru) 2003-02-27
CN1409640A (zh) 2003-04-09
ATE288765T1 (de) 2005-02-15
IL150129A0 (en) 2002-12-01
ES2236010T3 (es) 2005-07-16
BR0016334A (pt) 2002-09-10
WO2001043762A3 (en) 2002-01-10
DE20021079U1 (de) 2001-03-22

Similar Documents

Publication Publication Date Title
DK200000375U1 (da) Polypeptidsammensætninger med forbedret stabilitet.
SE0002102D0 (sv) Chemical compound
ATA10002000A (de) Antigene zusammensetzung
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
TR199901238T2 (xx) Asalak �ld�r�c� olarak 3-thiokarbamoylpirazol t�revleri.
TR199901674T2 (da)
PT1193270E (pt) Pirrolobenzodiazepinas
BRPI0414539A (pt) composto, composição farmacêutica, e, uso de um composto
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
ATE380822T1 (de) Funf-helix protein
MY133969A (en) Indoloquinazolinones
TR199802079T2 (xx) D-Manitol ve haz�rlanmas�.
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
DE60001850T2 (de) Chalcon coumarine
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
ES2186596T1 (es) Uso de inhibidores de il-18.
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
BR0207033A (pt) variantes de amina oxidase ap1
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.
WO2001070384A3 (de) Verwendung von duftalkoholalkoxylaten als solubilisierhilfsmittel

Legal Events

Date Code Title Description
URF Utility model: application refused